

FOI Ref: 26/179

25th March 2026

Eastbourne District General Hospital
Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer?

Yes.

If not, which other trust do you refer endometrial cancer patients to for SACT treatments?

Not applicable.

2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

• Dostarlimab (Jemperli)	3
• Dostarlimab (Jemperli) + Chemotherapy	0
• Hormone therapy (Progesterone or Letrozole)	0
• Lenvatinib + Pembrolizumab (Keytruda + Lenvima)	1
• Pembrolizumab monotherapy (Keytruda)	0
• Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)	3
• Durvalumab with Platinum-based Chemotherapy	0
• Pembrolizumab with Platinum-based Chemotherapy	0
• Any other SACT	8
• If the Trust are using Pembrolizumab subcutaneous injection, please can you provide the number of patients who received treatment with Pembrolizumab subcutaneous injection with Platinum-based Chemotherapy for Endometrial Cancer	0
The Trust does not currently use Pembrolizumab subcutaneous injection.	

3. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?

3

4. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:

• Dostarlimab (Jemperli) + Chemotherapy	1
• Hormone therapy (Progesterone or Letrozole)	0
• Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)	3
• Durvalumab with Platinum-based Chemotherapy	0
• Pembrolizumab with Platinum-based Chemotherapy	0
• Any other SACT	7
• If the Trust are using Pembrolizumab subcutaneous injection, please can you provide the number of patients who received treatment with Pembrolizumab subcutaneous injection with Platinum-based Chemotherapy for Endometrial Cancer	0
The Trust does not currently use Pembrolizumab subcutaneous injection.	

5. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

The Trust currently has no clinical trials or studies open for the treatment of endometrial cancer, and there are none in follow-up.

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
 East Sussex Healthcare NHS Trust
 0300 131 4716
 Core Hours of Business: Monday to Friday 9.00am to 4.00pm